Insmed is trading at $104.73 (-4.19%), with no clear explanation for the November 3 decline in available coverage. - Third-quarter results and raised 2026 sales guidance were reported October 29, followed by analyst target updates; these earlier developments do not establish a cause for today’s drop. - Biotech was higher while major indexes were mixed, so sector or broad-market factors are not a supported explanation; the reason for the decline remains unclear.